Caribou Biosciences Reports Third Quarter 2026 Financial Results
Globe Newswire•05/11/2026•16:05 ET
0
Key Highlights
- ➤Caribou (CRBU) reported Q3 revenue of $1.6 million, down from $2.2 million
- ➤Q3 net loss narrowed to $26.6 million, or $0.25 per share
- ➤Cash, equivalents, and marketable securities fell to $94.8 million
- ➤Caribou will discontinue vispa-cel and CB-011 clinical development activities
- ➤Caribou is exploring strategic alternatives, including merger, acquisition, or liquidation
BERKELEY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today reported financial results for the third quarter of 2026.
Third quarter 2026 financial results Licensing and other third-party revenue: Revenue from licensing and other third-party agreements was $1.6 million for the three months ended September 30, 2026, compared to $2.2 million for the same period in 2025.
Get started
Create a free account to read the full story.